Category: Solid Tumors

Olutasidenib, a Brain-Penetrant Mutant IDH1 Selective Inhibitor For AML Research

On December 1, 2022, FDA approved Rezlidhea (Olutasidenib) to treat adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible (IDH1) mutation. Olutasidenib (FT2102) is a highly potent, orally active, brain-penetrant, and selective inhibitor of mutant Isocitrate dehydrogenase 1 (IDH1). As a result, The IC50 values are...

SOR-C13 is a High-Affinity TRPV6 Antagonist for Advanced Solid Tumors Research

The Vanilloid group (TRPV) contains six members, from TRPV1 to TRPV6. TRPV5 and TRPV6 exhibit lower sequence identity to V1-V4, and different properties. Additionally, TRPV5 or TRPV6 is selective for calcium ions. The major function of TRPV5/6 is larger-scale calcium homeostasis. Besides, Mice with TRPV6 knock-outs exhibit defective intestinal...

EM127 is a SMYD3 Covalent Inhibitor

SMYD3 is a methyltransferase (MTase) catalyzing the methylation of specific lysine residues. Notably, it induces cell proliferation and regulates gene expression, including histones H3 (Histone H3 Lysine 4, H3K4) and H4 (Histone H4 Lysine 5, VEGFR1 receptor, AKT1, HER2, and MAP3K2 protein. Importantly, SMYD3 plays a role in transcriptional...

Apitolisib is an Orally Active Class I PI3K and mTORC1/2 Inhibitor

Activation of the pathway occurs following activating point mutations or amplification of the PIK3CA gene encoding the p110a PI3K isoform. Oncogenes such as PI3K, AKT, epidermal growth factor receptor (EGFR), and human epithelial growth factor receptor 2 (HER2) stimulate proliferation, growth, and survival by activating mTOR kinase. The mTOR...

Infigratinib (BGJ-398) is an Orally Active FGFR Inhibitor

The fibroblast growth factor receptor (FGFR) family of receptor tyrosine kinases (RTKs) comprises four members (FGFR1, FGFR2, FGFR3, and FGFR4) that share significant sequence homology. This family of RTKs serves as high-affinity receptors for the fibroblast growth factors (FGFs) that control cell proliferation, apoptosis, and differentiation and are involved...

Inupadenant is an Orally Active and Highly Selective A2A Receptor Antagonist

Adenosine receptors (AR), including P1 purinergic receptors, belong to G protein-coupled receptors (GPCR). Specifically, Adenosine is an autogenous acid in all tissues and body fluids. Besides, AR contains four subtypes, A1, A2A, A2B, and A3. They are activated by extracellular adenosine and play a central role in a wide...